Exploring the potential role of H3R antagonists in a number of CNS diseases like AD, epilepsy, attention deficit hyperactivity disorder (ADHD), narcolepsy (Witkin and Nelson, 2004; Savage et al., 2010; Kasteleijn-Nolst Trenite et al., 2013), SCH (Passani and Blandina, 2011; Baronio et al., 2015), and recently in TS (Rapanelli and Pittenger, 2016) and ASD (Baronio et al., 2015), suggest that H3R antagonists may be a potential therapeutic approach for treatment of several neurological disorders that are linked to cognitive impairment. Here, HRH3 is linked to Timothy syndrome.